Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …

Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

The clinical value of amphotericin B, the mainstay therapy for visceral leishmaniasis in
sodium antimony gluconate-nonresponsive zones of Bihar, India, is now threatened by the …

Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania
donovani and Leishmania infantum (Leishmania chagasi in the Americas). These …

Visceral leishmaniasis (VL), a deadly parasitic disease, is a major public health concern
globally. Countries affected by VL have signed the London Declaration on Neglected …

Leishmaniasis is a parasitic disease caused by hemoflagellate, Leishmania spp. The
parasite is transmitted by the bite of an infected female phlebotomine sandfly. The disease is …

Leishmania infections span a range of clinical syndromes and impact humans from many
geographic foci, but primarily the world's poorest regions. Transmitted by the bite of a female …

For the past 15 years, trials of combination therapy options for visceral leishmaniasis have
been conducted with the aim of identifying effective, and safe treatment regimens that were …

As a neglected tropical disease, Leishmaniasis is significantly instigating morbidity and
mortality across the globe. Its clinical spectrum varies from ulcerative cutaneous lesions to …

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …